# Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

> **NCT04173338** · PHASE1 · TERMINATED · sponsor: **Augusta University** · enrollment: 9 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Non-squamous Non-small-cell Lung Cancer
- Urothelial Carcinoma
- Malignant Mesothelioma

## Interventions

- **DRUG:** Cabozantinib
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT04173338
- **Lead sponsor:** Augusta University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-23
- **Primary completion:** 2022-03-28
- **Final completion:** 2022-03-28
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Closed by IRB on 3/28/22
- **Last updated:** 2022-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04173338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04173338, "Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04173338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*